Latest News

Vanguard FTSE Developed Markets ETF (NYSEARCA:VEA) Shares Sold by Appleton Partners Inc. MA

Vanguard FTSE Developed Markets ETF (NYSEARCA:VEA) Shares Sold by Appleton Partners Inc. MA

Appleton Partners Inc. MA lowered its position in Vanguard FTSE Developed Markets ETF (NYSEARCA:VEA) by 4.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 70,197 shares of the company’s stock after selling 3,205 shares during the period. Appleton Partners Inc. MA’s holdings in Vanguard FTSE Developed Markets ETF were worth […]

by November 22, 2019
China Mobile Ltd. (NYSE:CHL) Shares Sold by Atlas Capital Advisors LLC

China Mobile Ltd. (NYSE:CHL) Shares Sold by Atlas Capital Advisors LLC

Atlas Capital Advisors LLC lowered its position in China Mobile Ltd. (NYSE:CHL) by 15.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 10,716 shares of the Wireless communications provider’s stock after selling 1,995 shares during the period. Atlas Capital Advisors LLC’s holdings in China Mobile were worth $444,000 as of […]

by November 22, 2019
Fuchs Petrolub (FRA:FPE) PT Set at €36.10 by Warburg Research

Fuchs Petrolub (FRA:FPE) PT Set at €36.10 by Warburg Research

Fuchs Petrolub (FRA:FPE) has been given a €36.10 ($41.98) price target by analysts at Warburg Research in a research note issued on Tuesday, November 5th, Borsen Zeitung reports. The brokerage presently has a “neutral” rating on the stock. Warburg Research’s target price suggests a potential downside of 1.77% from the stock’s current price. A number of other equities analysts have […]

by November 22, 2019
-$0.51 EPS Expected for Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) This Quarter

-$0.51 EPS Expected for Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) This Quarter

Wall Street analysts predict that Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) will announce earnings of ($0.51) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Zynerba Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.52) and the highest is ($0.50). Zynerba Pharmaceuticals posted earnings of ($0.44) per share during the same quarter last year, which would […]

by November 22, 2019
GW Pharmaceuticals PLC- (NASDAQ:GWPH) Rating Reiterated by Evercore ISI

GW Pharmaceuticals PLC- (NASDAQ:GWPH) Rating Reiterated by Evercore ISI

GW Pharmaceuticals PLC- (NASDAQ:GWPH)‘s stock had its “buy” rating restated by analysts at Evercore ISI in a research note issued on Monday, November 11th, AnalystRatings.com reports. Other research analysts have also issued reports about the company. HC Wainwright reaffirmed a “buy” rating on shares of GW Pharmaceuticals PLC- in a report on Friday, November 8th. ValuEngine raised GW Pharmaceuticals PLC- […]

by November 22, 2019